Skip to main content

Welcome to Janssen UK

Visit Janssen Global

News Press Releases

2021-08-10 17:30

PONVORY®▼ (ponesimod), a Once Daily, Oral Therapy Authorised in Great Britain for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS) with Active Disease Defined by Clinical or Imaging Features

2021-01-29 18:00

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

2020-11-16 00:15

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

2020-09-08 06:30

Biopharma Leaders Unite To Stand With Science

2020-08-14 14:00

United Kingdom

Johnson & Johnson Announces Collaboration in Principle with the United Kingdom on Additional Phase 3 Study and Agreement to Supply its COVID-19 Vaccine Candidate

2020-03-18 21:00

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2

2020-01-29 14:00

Janssen announces European licence extension for Erleada®▼ (apalutamide) for patients with metastatic hormone-sensitive prostate cancer

2020-01-23 14:00

Janssen Responds to NICE Draft Guidance for Stelara® (USTEKINUMAB) in Ulcerative Colitis

2020-01-13 19:00

Scottish Medicines Consortium recommends Zytiga® (abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for men with aggressive, early prostate cancer for use in NHS Scotland